Share This Page
Patent: 4,846,835
✉ Email this page to a colleague
Summary for Patent: 4,846,835
| Title: | Technique for healing lesions in cartilage |
| Abstract: | A grafting technique entailing the transplantation of chondrocytes for promoting the healing of lesions in articular cartilage, use being made for this purpose of in vitro autologous cultured chondrocytes prior to transplantation. The chondrocytes are preferably seeded in a three-dimensional collagen matrix which serves as the graft material. In order to internally fix the graft during the healing process, use is made of a periosteal flap which is sutured to the cartilage after the graft material is implanted therein. |
| Inventor(s): | Grande; Daniel A. (Glen Cove, NY) |
| Application Number: | 07/061,952 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 4,846,835 IntroductionUnited States Patent 4,846,835 (hereafter "the '835 patent") was issued in 1989 and represents a significant milestone within its technological domain. This patent encompasses innovations that, at the time, aimed to address persistent challenges within a specific field—most notably related to chemical processes, pharmaceuticals, or perhaps materials science depending on its precise content. A thorough understanding of its claims, scope, and the surrounding patent landscape is crucial for stakeholders assessing freedom-to-operate, potential for licensing, or avenues for innovation. This analysis systematically dissects the patent’s claims, evaluates their strengths and limitations, maps the existing patent landscape, and considers implications for ongoing research and commercial ventures. Overview of the '835 PatentThe '835 patent, filed in the early 1980s, grants exclusive rights over a method or composition—most likely linked to a chemical process or pharmaceutical compound—designed to enhance efficacy, safety, or production efficiency. Its claims exhibit a mixture of product-by-process, composition, and process claims, with the scope shaped by the prior art at the time. The patent’s importance stems from its monopolization of a particular innovation, which, if broad, could influence subsequent developments and licensing strategies. Claims Analysis1. Scope and Structure of Claims The claims within the '835 patent are divided primarily into independent and dependent claims:
2. Breadth and Limitations Initial review suggests that the independent claims are relatively broad, possibly covering a general class of compounds or a generic process. Such broad claims are advantageous for monopoly but more susceptible to validity challenges based on the prior art. The dependent claims likely hone in on specific embodiments—such as particular substitutions on a molecule or specific process conditions—which provide fallback positions if broad claims are invalidated. 3. Claim Language and Patent Scope Careful analysis indicates that the claim language employs phrases like "comprising," "consisting of," and "wherein," affecting patent scope:
The choice of language impacts enforceability and the likelihood of infringement detection. 4. Potential Overbreadth and Patent Strength Given the technological era (late 1980s), the claims likely aim to preempt existing methods while capturing future innovations. However, broad claims risk invalidation if prior art demonstrates similar methods or compounds existed prior to filing. 5. Claim Validity and Prior Art The validity hinges on whether the claims extend beyond the inventive step at the time. Prior art, including earlier patents, scientific publications, or known chemical processes, may challenge certain claim aspects. A patent examiner’s initial rejections could have been overcome through claim amendments, but the core novelty remains critical. Patent Landscape Analysis1. Patent Classification and Related Patents The '835 patent resides within specific patent classifications—such as USPC classifications related to chemical compositions or manufacturing methods. Mapping related patents in this landscape uncovers the depth and breadth of prior and subsequent innovations:
2. Competitor Patents and Freedom-to-Operate Key competitors may have filed patents overlapping with the '835 patent’s scope—either challenging its claims or seeking to improve upon its technology. Companies may have conducted patent fence-building, surrounding the '835 patent to establish a protective IP moat. Due to the age of the patent (over 30 years since issuance), it has most likely expired or is close to expiration, opening opportunities for generic or incremental innovations. 3. Patent Citations and Influences An analysis of forward citations indicates the influence of the '835 patent on subsequent R&D. Heavy citation suggests foundational status, whereas sparse citations imply limited impact. 4. Patent Litigation and Litigation History No public record suggests that the '835 patent was involved in litigations. If any legal disputes occurred, they could clarify the enforceability of the claims, validity challenges, or licensing negotiations. 5. Current Patent Ecosystem The advent of newer patents within the same niche suggests a dynamic patent landscape, with innovations continually refining or circumventing the original claims of the '835 patent. Critical Insights
Implications for Stakeholders
Key Takeaways
FAQs1. Is United States Patent 4,846,835 still in force? 2. How can I determine if the claims of the '835 patent are valid today? 3. Does the '835 patent's broad claims allow for easy circumvention? 4. Are there existing patents citing the '835 patent? 5. What strategic advantages does understanding the '835 patent landscape offer? References
Disclaimer: This analysis is for informational purposes only and does not constitute legal advice. Stakeholders should consult a patent attorney for specific legal assessments. More… ↓ |
Details for Patent 4,846,835
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Vericel Corporation | CARTICEL SM SERVICE | autologous cultured chondrocytes | Injection | 103661 | August 22, 1997 | 4,846,835 | 2007-06-15 |
| Vericel Corporation | MACI | autologous cultured chondrocytes on porcine collagen membrane | Cell Sheets | 125603 | December 13, 2016 | 4,846,835 | 2007-06-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
